Spyre Therapeutics, Inc.
Company Stats
- Market Cap
- $7.9B
- as of Sep 30, 2026
- Shares Outstanding
- 88.2M
- Free Float
- 64.3%
Income Statement
- Revenue
- $0
- Operating Income
- -$209.6M
- Net Income
- -$155.2M
- EBITDA
- -$209.6M
Balance Sheet
- Cash & Equivalents
- $85.7M
Returns & Capital
- SBC, 3Y Avg
- $36.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | — | — |
| FY2024 | $0 | -$157.4M | — |
| FY2023 | $886,000 | -$99.9M | -11276.5% |
| FY2022 | $2.3M | -$80.2M | -3442.8% |
| FY2021 | $18.7M | -$54.3M | -289.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Nuvei to Acquire Payoneer for $2.75 Billion